Theranostic etoposide phosphate/indium nanoparticles for cancer therapy and imaging
Source abstract
Abstract
Etoposide phosphate (EP), a water-soluble anticancer prodrug, is widely used for treatment of many cancers. After administration it is rapidly converted to etoposide, its parent compound, which exhibits anticancer activity. Difficulty in parenteral administration necessitates the development of a suitable nanoparticle delivery system for EP. Here we have used indium both as a carrier to deliver etoposide phosphate to tumor cells and as a SPECT imaging agent through incorporation of (111)In. Etoposide phosphate was successfully encapsulated together with indium in nanoparticles, and exhibited dose dependent cytotoxicity and induction of apoptosis in cultured H460 cancer cells via G2/M cell cycle arrest. In a mouse xenograft lung cancer model, etoposide phosphate/indium nanoparticles induce tumor cell apoptosis, leading to significant enhancement of tumor growth inhibition compared to the free drug.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery
Eshelman School of Pharmacy
University of North Carolina at Chapel Hill
Chapel Hill, USA
UNC and NCSU Joint Department of Biomedical Engineering
References (29)
Show source-provided references
1. Hande · Eur. J. Cancer · 1998 · 34 · 151410.1016/S0959-8049(98)00228-7 ↗
2. Larsen · Prog. Cell Cycle Res. · 1996 · 2 · 22910.1007/978-1-4615-5873-6_22 ↗
3. Fields · Clin. Cancer Res. · 1995 · 1 · 105
4. Rose · Invest. New Drugs · 1990 · 8 · S2510.1007/BF00171981 ↗
5. Senter · Proc. Natl. Acad. Sci. U. S. A. · 1988 · 85 · 484210.1073/pnas.85.13.4842 ↗
6. Heath · Annu. Rev. Med. · 2008 · 59 · 25110.1146/annurev.med.59.061506.185523 ↗
7. Torchilin · Nat. Rev. Drug Discovery · 2014 · 13 · 81310.1038/nrd4333 ↗
8. Fang · Adv. Drug Delivery Rev. · 2011 · 63 · 13610.1016/j.addr.2010.04.009 ↗
9. Ramishetti · Ther. Delivery · 2012 · 3 · 142910.4155/tde.12.127 ↗
10. Chen · Nanotechnology · 2012 · 23 · 04510410.1088/0957-4484/23/4/045104 ↗
11. Qian · Int. J. Nanomed. · 2012 · 7 · 5781
12. Lamprecht · J. Controlled Release · 2006 · 112 · 20810.1016/j.jconrel.2006.02.014 ↗
13. Kalhapure · Colloids Surf., B · 2013 · 105 · 21510.1016/j.colsurfb.2013.01.011 ↗
14. Callewaert · J. Biomed. Mater. Res., Part A · 2013 · 101 · 131910.1002/jbm.a.34442 ↗
15. Snehalatha · Drug Delivery · 2008 · 15 · 27710.1080/10717540802006500 ↗
16. Shah · J. Appl. Polym. Sci. · 2013 · 127 · 499110.1002/app.38107 ↗
17. Tang · Biomaterials · 2010 · 31 · 33910.1016/j.biomaterials.2009.09.033 ↗
18. Psimadas · J. Pharm. Sci. · 2012 · 101 · 227110.1002/jps.23146 ↗
19. Kelkar · Bioconjugate Chem. · 2011 · 22 · 187910.1021/bc200151q ↗
20. Kairemo · Eur. J. Nucl. Med. · 1996 · 23 · 63110.1007/BF00834524 ↗
21. Kairemo · J. Nucl. Biol. Med. · 1994 · 38 · 135
22. Zhang · Biomaterials · 2013 · 34 · 344710.1016/j.biomaterials.2013.01.063 ↗
23. Sleiman · Clin. Cancer Res. · 2000 · 6 · 3756
24. Chaitanya · Cell Commun. Signaling · 2010 · 8 · 3110.1186/1478-811X-8-31 ↗
25. Smith · Br. J. Cancer · 1994 · 70 · 91410.1038/bjc.1994.420 ↗
26. Satterlee · J. Controlled Release · 2015 · 217 · 17010.1016/j.jconrel.2015.08.048 ↗
27. Witterland · Pharm. World Sci. · 1996 · 18 · 16310.1007/BF00820727 ↗
28. Beijnen · Int. J. Pharm. · 1988 · 41 · 16910.1016/0378-5173(88)90149-4 ↗
29. Karl · Appl. Environ. Microbiol. · 1980 · 40 · 54910.1128/AEM.40.3.549-561.1980 ↗